Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Yang, Deok Hwan | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Chong, So Young | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Do, YoungRok | - |
dc.contributor.author | Lim, Sung-Nam | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Chung, Joo-Seop | - |
dc.date.accessioned | 2021-09-04T04:37:18Z | - |
dc.date.available | 2021-09-04T04:37:18Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-01 | - |
dc.identifier.issn | 0301-472X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89999 | - |
dc.description.abstract | We compared the outcomes of patients with higher-risk diffuse large B-cell lymphoma (DLBCL) who were treated with either up-front autologous stem cell transplantation (ASCT) or salvage chemotherapy followed by delayed ASCT after relapse. Data for 122 DLBCL patients who underwent ASCT as up-front or salvage treatment were analyzed. The 3-year overall survival (OS) rate in DLBCL patients who underwent up-front ASCT was 76.6%, and the rate for those who underwent delayed ASCT was 60.9% (p = 0.017). In a subgroup analysis of patients with a high-intermediate/high-risk age-adjusted International Prognostic Index, achievement of complete remission translated into improved OS in the up-front ASCT group, whereas patients who achieved partial remission had similar OS rates in both groups. The up-front ASCT group had improved OS in patients aged <50 years or with good performance status, whereas the OS rates of both groups were similar in patients aged >= 60 years or with poor performance status. When the OS outcome is analyzed by the number of factors (no complete remission during R-CHOP induction chemotherapy, age >= 50 years, and performance status the 3-year OS rates of patients with zero or one, two, and three clinical factors were 80.2%, 51.6%, and 0%, respectively (p < 0.001). In conclusion, in higher-risk DLBCL patients, induction chemotherapy followed by up-front ASCT may have a survival benefit compared with induction chemotherapy alone in highly selected patients who have achieved a complete remission, who are aged <50 years, and who have a good performance status at diagnosis. Copyright (C) 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | HIGH-DOSE CHEMOTHERAPY | - |
dc.subject | NON-HODGKINS-LYMPHOMA | - |
dc.subject | DETUDE DES LYMPHOMES | - |
dc.subject | THERAPY | - |
dc.subject | RITUXIMAB | - |
dc.subject | YOUNG | - |
dc.subject | CHOEP-14 | - |
dc.subject | IMPROVES | - |
dc.title | Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1016/j.exphem.2015.08.008 | - |
dc.identifier.scopusid | 2-s2.0-84949730904 | - |
dc.identifier.wosid | 000366785400001 | - |
dc.identifier.bibliographicCitation | EXPERIMENTAL HEMATOLOGY, v.44, no.1, pp.3 - 13 | - |
dc.relation.isPartOf | EXPERIMENTAL HEMATOLOGY | - |
dc.citation.title | EXPERIMENTAL HEMATOLOGY | - |
dc.citation.volume | 44 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 3 | - |
dc.citation.endPage | 13 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | HIGH-DOSE CHEMOTHERAPY | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | DETUDE DES LYMPHOMES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | YOUNG | - |
dc.subject.keywordPlus | CHOEP-14 | - |
dc.subject.keywordPlus | IMPROVES | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.